Linked Life Data

12414873

Source:http://linkedlifedata.com/resource/pubmed/id/12414873

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2002-11-4
pubmed:abstractText
Combination antiretroviral therapy for the treatment of human immunodeficiency virus type 1-infected patients is associated with development of the lipodystrophy syndrome (LD). We previously showed that plasma levels of free fatty acids are higher in patients with lipodystrophy. The purpose of this study was to evaluate the postabsorptive rate of lipolysis, using [(2)H(5)]glycerol infusion, the resting energy expenditure (REE) measured by indirect calorimetry, and the responses of both to epinephrine infusion ( approximately 15 ng/kg.min) in patients with LD. Results were compared with those obtained in five matched human immunodeficiency virus type 1-infected patients. The postabsorptive rate of appearance of glycerol did not differ between the two groups. There was no difference in the lipolytic response to epinephrine, although the response in the LD group was delayed (P < 0.001). The postabsorptive REE adjusted for lean body mass was lower and remained lower during epinephrine infusion in the LD group. Postabsorptive norepinephrine concentrations were higher and remained elevated during epinephrine infusion in the LD group. We conclude that the lipolytic response to epinephrine in the LD group was normal, albeit delayed. Norepinephrine concentrations were increased in patients with lipodystrophy, indicating increased sympathetic activity. Postabsorptive REE was lower in the patients with lipodystrophy. Our data suggest that highly active antiretroviral therapy-associated lipodystrophy normalizes the REE, but has only minor effects on lipolysis as a result of concomitant sympathetic stimulation of adipose tissue.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0021-972X
pubmed:author
pubmed:issnType
Print
pubmed:volume
87
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5066-71
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:12414873-Acquired Immunodeficiency Syndrome, pubmed-meshheading:12414873-Adult, pubmed-meshheading:12414873-Antiretroviral Therapy, Highly Active, pubmed-meshheading:12414873-Body Mass Index, pubmed-meshheading:12414873-CD4 Lymphocyte Count, pubmed-meshheading:12414873-Calorimetry, Indirect, pubmed-meshheading:12414873-Deuterium, pubmed-meshheading:12414873-Energy Metabolism, pubmed-meshheading:12414873-Epinephrine, pubmed-meshheading:12414873-Food, pubmed-meshheading:12414873-Glycerol, pubmed-meshheading:12414873-Humans, pubmed-meshheading:12414873-Insulin, pubmed-meshheading:12414873-Kinetics, pubmed-meshheading:12414873-Lipodystrophy, pubmed-meshheading:12414873-Lipolysis, pubmed-meshheading:12414873-Male, pubmed-meshheading:12414873-Middle Aged, pubmed-meshheading:12414873-Norepinephrine, pubmed-meshheading:12414873-Rest
pubmed:year
2002
pubmed:articleTitle
Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure.
pubmed:affiliation
International Antiviral Therapy Evaluation Center, Academic Medical Center, T0-119, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. m.vandervalk@amc.uva.nl
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't